Once-daily dosing of Merck's Isentress fails in HIV
This article was originally published in Scrip
Merck has hit another setback in its development of its HIV drugs, after it halted on efficacy grounds a Phase III study comparing an investigational once-daily dose of its integrase inhibitor Isentress (raltegravir) with the approved twice-daily dose in treatment-naïve HIV-1 infected patients.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.